Free Trial

DaVita Inc. $DVA Shares Sold by IFM Investors Pty Ltd

DaVita logo with Medical background

Key Points

  • IFM Investors Pty Ltd has reduced its stake in DaVita Inc. by 27.4%, now holding 10,117 shares valued at approximately $1.44 million.
  • DaVita reported a net income of $2.95 per share for the latest quarter, surpassing estimates and showing a 6.1% increase in revenue year-over-year.
  • Analysts have varied opinions on DaVita's stock, with recent ratings including a downgrade from Barclays and an upgrade from Wall Street Zen, reflecting a mixed outlook on its performance.
  • Five stocks to consider instead of DaVita.

IFM Investors Pty Ltd decreased its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 27.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,117 shares of the company's stock after selling 3,815 shares during the quarter. IFM Investors Pty Ltd's holdings in DaVita were worth $1,441,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its position in shares of DaVita by 2.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock valued at $531,000 after purchasing an additional 69 shares in the last quarter. UMB Bank n.a. raised its stake in shares of DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after acquiring an additional 76 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in shares of DaVita by 8.9% in the first quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock valued at $148,000 after acquiring an additional 79 shares in the last quarter. Mather Group LLC. raised its stake in shares of DaVita by 7.0% in the first quarter. Mather Group LLC. now owns 1,201 shares of the company's stock valued at $184,000 after acquiring an additional 79 shares in the last quarter. Finally, National Pension Service increased its holdings in DaVita by 74.3% in the first quarter. National Pension Service now owns 197 shares of the company's stock valued at $30,000 after buying an additional 84 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the transaction, the insider owned 26,038 shares in the company, valued at approximately $3,905,700. This represents a 8.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.50% of the company's stock.

DaVita Price Performance

Shares of NYSE:DVA opened at $131.21 on Tuesday. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18. DaVita Inc. has a fifty-two week low of $126.07 and a fifty-two week high of $179.60. The firm has a 50-day simple moving average of $136.91 and a 200 day simple moving average of $140.91. The company has a market cap of $9.38 billion, a PE ratio of 12.90, a P/E/G ratio of 0.93 and a beta of 1.13.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the prior year, the firm earned $2.00 EPS. The company's revenue for the quarter was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

DVA has been the topic of several research reports. Barclays dropped their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Truist Financial set a $148.00 price objective on shares of DaVita in a research note on Friday, August 8th. Bank of America dropped their price objective on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating for the company in a research note on Wednesday, September 10th. Finally, Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Reduce" and an average target price of $158.00.

View Our Latest Stock Report on DVA

DaVita Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Read More

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DaVita Right Now?

Before you consider DaVita, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.

While DaVita currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.